|
End-of-day quote
Nasdaq
2026-10-27
|
5-day change | 1st Jan Change | ||
| 0.4746 USD | +18.92% |
|
+16.67% | -99.39% |
| 10-08 | RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating | MT |
| 09-24 | SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc.. | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.36M | - | - | - | - | - |
| 1,148B | |||||
| 652B | |||||
| 505B | |||||
| 384B | |||||
| 348B |
- Stock Market
- Stocks
- ONCO Stock
- Charts Onconetix, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
